Onconetix Net Worth
Onconetix Net Worth Breakdown | ONCO |
Onconetix Net Worth Analysis
Onconetix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Onconetix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Onconetix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Onconetix's net worth analysis. One common approach is to calculate Onconetix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Onconetix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Onconetix's net worth. This approach calculates the present value of Onconetix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Onconetix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Onconetix's net worth. This involves comparing Onconetix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Onconetix's net worth relative to its peers.
To determine if Onconetix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Onconetix's net worth research are outlined below:
| Onconetix generated a negative expected return over the last 90 days | |
| Onconetix has high historical volatility and very poor performance | |
| Onconetix has a very high chance of going through financial distress in the upcoming years | |
| Onconetix currently holds 9.45 M in liabilities. Onconetix has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Onconetix's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (58.69 M) with profit before overhead, payroll, taxes, and interest of 911.93 K. | |
| Onconetix currently holds about 113.36 K in cash with (10.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85. | |
| Roughly 58.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Reversal Confirmed Onconetix Inc. Stock Rallies Above MA - Smart Investment Tips Gaining Popularity Among Analysts - metal.it |
Onconetix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Onconetix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Onconetix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Onconetix Target Price Consensus
Onconetix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Onconetix's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Onconetix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Onconetix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Onconetix, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOnconetix Target Price Projection
Onconetix's current and average target prices are 2.67 and 9.00, respectively. The current price of Onconetix is the price at which Onconetix is currently trading. On the other hand, Onconetix's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Onconetix Target Price
Follow Onconetix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.53 M.Market Cap |
|
Project Onconetix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (51.82) | (49.23) | |
| Return On Capital Employed | (5.71) | (5.43) | |
| Return On Assets | (2.08) | (1.98) | |
| Return On Equity | (6.11) | (5.80) |
When accessing Onconetix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Onconetix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Onconetix's profitability and make more informed investment decisions.
Evaluate Onconetix's management efficiency
Onconetix has return on total asset (ROA) of (0.0825) % which means that it has lost $0.0825 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.8006) %, meaning that it created substantial loss on money invested by shareholders. Onconetix's management efficiency ratios could be used to measure how well Onconetix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of August 2025, Return On Tangible Assets is likely to grow to -49.23. In addition to that, Return On Capital Employed is likely to grow to -5.43. At this time, Onconetix's Total Assets are very stable compared to the past year. As of the 7th of August 2025, Other Current Assets is likely to grow to about 202.1 K, while Non Current Assets Total are likely to drop about 20 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 297.54 | 312.42 | |
| Tangible Book Value Per Share | (539.89) | (512.89) | |
| Enterprise Value Over EBITDA | (0.18) | (0.19) | |
| Price Book Value Ratio | 0.18 | 0.17 | |
| Enterprise Value Multiple | (0.18) | (0.19) | |
| Price Fair Value | 0.18 | 0.17 | |
| Enterprise Value | 264 M | 234.7 M |
Onconetix showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 4.973 | Revenue | Quarterly Revenue Growth (0.85) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Onconetix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Onconetix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Onconetix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altos Venture Ag over three weeks ago Disposition of 241514 shares by Altos Venture Ag of Onconetix subject to Rule 16b-3 | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading |
Onconetix Earnings per Share Projection vs Actual
Onconetix Corporate Management
| Theodore Yoho | Head Development | Profile | |
| MBA MA | Senior Development | Profile | |
| Andrew Skibo | Global Operations | Profile | |
| MD MBA | Chief Officer | Profile | |
| Christian Bruhlmann | Chief Officer | Profile | |
| Dr Very | Senior Development | Profile | |
| Erin Henderson | Consultant | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (161.50) | Revenue Per Share | Quarterly Revenue Growth (0.85) | Return On Assets | Return On Equity |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.